Dr. Nabil Hajji is a world-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in several types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment. With more than 70 publications in the main scientific journals worldwide and an i10-index of 26.

He is currently a doctor at the Center for Pharmacology and Therapeutics of the Department of Medicine of Imperial College London, PhD in Molecular Oncology from the University of Seville and postdoctoral at the Karolinska Institute in Stockholm, has worked as a researcher at the Institute of Oncology Studies of the University of Birmingham, at the Institute of Cellular and Molecular Sciences of Queen Mary University and at Harvard University where he currently continues to collaborate  as a researcher.

Its discovery at Imperial College London in the journal JCI (The Journal of Clinical Investigation) has reached the phase of Phase I clinical trial.